MedPath

Clinical Trial of Gliclazide in MODY 1,3 and 12

Not Applicable
Conditions
Health Condition 1: - Health Condition 2: E139- Other specified diabetes mellituswithout complications
Registration Number
CTRI/2020/03/023968
Lead Sponsor
DrVMohan
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Adult Patients aged 7-30 (ends inclusive) of either gender diagnosed who are diagnosed with MODY 1, MODY 3 or MODY 12

2.Body Mass Index ( < 30 kg/m2)

3.Family history of diabetes in one or both of the parents

4.Duration of diabetes less than 2 years

5.Patients who understands the nature of study and willing to provide a written informed consent

Exclusion Criteria

Patient will excluded if they have any of the following:

1.Type 1 diabetes

2.Type 2 diabetes

3.Gestational diabetes

4.Fibrocalculous pancreatic diabetes

5.Presence of acanthosis nigricans or severe obesity

6.History of serious infection / surgical procedure / Severe trauma in past 4 weeks or planned surgery during the study period of 12 weeks

7.History or evidence of significant cardiovascular disorder including but not limited to, heart failure, myocardial infarction or any conduction abnormality on ECG viz QT prolongation, Arrhythmias

8.History or risk of Acute Pancreatitis

9.History of Chronic Alcoholism or drug abuse

10.Pregnant or breast-feeding women

11.A subject who is judged by the investigator as inappropriate to participate in the study for any reason other than those mentioned above.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Change in HbA1c level from baseline to end of 52 weeksTimepoint: 1.Change in HbA1c level from baseline to end of 52 weeks
Secondary Outcome Measures
NameTimeMethod
2.Change in fasting plasma glucose (FPG) and post prandial plasma glucose (PPPG) level from baseline to end of 52 weeks.Timepoint: 1.Incidence of adverse events and serious adverse events <br/ ><br>2.hypoglycemia events <br/ ><br>3.vital signs (weight, BMI) and Laboratory values <br/ ><br>
© Copyright 2025. All Rights Reserved by MedPath